We investigated the relationship between basal ganglia volume and treatment response to the atypical antipsychotic medication risperidone in unmedicated patients with schizophrenia. Basal ganglia volumes included the bilateral caudate, putamen, and pallidum and were measured using the Freesurfer automated segmentation pipeline in 23 subjects. Also, baseline symptom severity, duration of illness, age, gender, time off medication, and exposure to previous antipsychotic were measured. Treatment response was significantly correlated with all three regions of the bilateral basal ganglia (caudate, putamen, and pallidum), baseline symptom severity, duration of illness, and age but not gender, time off antipsychotic medication, or exposure to previous antipsychotic medication. The caudate volume was the basal ganglia region that demonstrated the strongest correlation with treatment response and was significantly negatively correlated with patient age. Caudate volume was not significantly correlated with any other measure. We demonstrated a novel finding that the caudate volume explains a significant amount of the variance in treatment response over the course of 6 weeks of risperidone pharmacotherapy even when controlling for baseline symptom severity and duration of illness.
a b s t r a c t
We investigated the relationship between basal ganglia volume and treatment response to the atypical antipsychotic medication risperidone in unmedicated patients with schizophrenia. Basal ganglia volumes included the bilateral caudate, putamen, and pallidum and were measured using the Freesurfer automated segmentation pipeline in 23 subjects. Also, baseline symptom severity, duration of illness, age, gender, time off medication, and exposure to previous antipsychotic were measured. Treatment response was significantly correlated with all three regions of the bilateral basal ganglia (caudate, putamen, and pallidum), baseline symptom severity, duration of illness, and age but not gender, time off antipsychotic medication, or exposure to previous antipsychotic medication. The caudate volume was the basal ganglia region that demonstrated the strongest correlation with treatment response and was significantly negatively correlated with patient age. Caudate volume was not significantly correlated with any other measure. We demonstrated a novel finding that the caudate volume explains a significant amount of the variance in treatment response over the course of 6 weeks of risperidone pharmacotherapy even when controlling for baseline symptom severity and duration of illness.
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Introduction
The schizophrenia patient population has a variable response to antipsychotic drugs (APDs). Between 20% and 30% of patients are categorized as treatment-resistant, showing little to no improvement following treatment with APDs (Conley and Buchanan, 1997) . Considering that schizophrenia is a severe mental illness with a world-wide prevalence of approximately 1% (Jablensky et al., 1992) , this variability in treatment response is a major problem in the field of psychiatry. Currently, it takes clinicians several weeks to decide if a treatment is ineffective and initiate an alternate treatment therapy (van den Oord et al., 2009) . During these extended trial periods, patients can remain symptomatic and thus at increased risk of hospitalization (van den Oord et al., 2009). The discovery of neural biomarkers using noninvasive magnetic resonance imaging (MRI) to predict treatment response could improve both the speed and quality of treatment in psychiatric diseases such as schizophrenia. The first step in creating usable biomarkers for the clinic is to discover variables that are associated with variance in factors such as treatment response. Later these factors can be tested at the individual level in larger groups of patients using predictive techniques that employ bootstrapping techniques to yield metrics such as sensitivity and specificity. The scope of this article is not to conduct predictive modeling at the individual subject level but to further investigate if basal ganglia volume warrants such larger studies.
The goal of this study was to investigate whether the volumes of regions of the basal ganglia are associated with treatment response to an atypical APD in patients with schizophrenia. Volumes were measured from scans obtained before treatment, when patients were unmedicated, and treatment response was evaluated following 6 weeks of treatment with risperidone. Previous work has shown that the volumes of the subcortical regions included in the basal ganglia are associated with treatment response to APDs (Buchsbaum et al., 2003; Okugawa et al., 2007; Molina et al., 2010 Molina et al., , 2011 Li et al., 2011; ) . However, none of the previous articles have controlled for other factors that can also be used to explain variance in treatment response.
Treatment response to APD therapy has also been shown to be associated with baseline symptom severity (Bartkó et al., 1990; McEvoy et al., 1991; Cuesta et al., 1994; Crespo-Facorro et al., 2007) , duration of psychotic illness (McEvoy et al., 1991; Keck et al., 1995) 
